Drug intelligence / Profile preview

AGN201781

Development stage: Discontinued
Lead developer: Allergan
Modality: Small Molecules
Administration: Oral

Overview

AGN201781 is an investigational oral small molecule drug that was developed for the treatment of neuropathic pain, specifically postherpetic neuralgia and post-traumatic peripheral neuralgia. The drug was initially developed by Allergan and later associated with AbbVie following corporate acquisition. Its mechanism of action is not definitively established in public sources, but it has been described as an α-adrenergic receptor agonist. Clinical development reached Phase 2 trials before being discontinued, with no approved indications or known adverse events reported[1][2][3][4].

Targets

ADRA1 (Alpha-1 adrenergic receptor family)

Beyond the preview

Go deeper on AGN201781.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGN201781.

Explore the full profile